Drug Trial Radar · NCT07206849
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
79
Planned (sponsor's estimate)
Start
Feb 2027
Primary completion
Feb 2030
Study completion Feb 2037
Sponsor
- Lead sponsor
- Nationwide Children's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Day One Biopharmaceuticals, Inc.
- First posted
- Oct 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 39 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (MAPK) that this drug targets. The main question the study aims to answer is whether tovorafenib can prolong the life of patients diagnosed with HGG, including DIPG.
Conditions
- High Grade Glioma (HGG) of the Brain With BRAF Aberration
- High Grade Glioma (III or IV)
- Diffuse Intrinsic Pontine Glioma
- High Grade Glioma
- WHO Grade 3 Glioma
- WHO Grade 4 Glioma
- Metastatic Brain Tumor
Interventions
TovorafenibDrug
Tovorafenib will be given orally once weekly (QW) throughout each cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival Stratum ATime frame: 6 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.